Benzinga | Jul 20, 2021 11:04AM EDT

NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia

* NeuroMetrix Inc's (NASDAQ:NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults.

* Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.

* Quell is a wearable electrical nerve stimulator. It utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night.

* The data submitted by NeuroMetrix in support of the Breakthrough Designation included results of 119 subjects.

* In an intention-to-treat (ITT) analysis of all subjects, 56% of those on active treatment exhibited a clinically meaningful improvement in health-related quality-of-life compared to 35% that received sham therapy.

* The Company expects to launch Quell for fibromyalgia in the second half of 2022.

* Price Action: NURO shares jump 43.9% at $4.69 during the market session on the last check Tuesday.

* Related content: Benzinga's Full FDA Calendar.